All In Biotech

Drug Trial Radar · NCT05972044

A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Solriamfetol in Adults With ADHD.

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 516 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

516

Actual

Start

Jul 6, 2023

Primary completion

Feb 7, 2025

Study completion Mar 14, 2025

Sponsor

Lead sponsor
Axsome Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.

Conditions

  • ADHD

Interventions

  • Solriamfetol 150 mgDrug

    Solriamfetol tablets, taken once daily

  • Solriamfetol 300 mgDrug

    Solriamfetol tablets, taken once daily

  • PlaceboDrug

    Placebo tablets, taken once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 6 in the AISRS total scoreTime frame: 6 weeks

Locations

42 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Site

    Encino, California

  • Clinical Research Site

    Garden Grove, California

  • Clinical Research Site

    Newport Beach, California

  • Clinical Research Site

    Riverside, California

  • Clinical Research Site

    Santa Ana, California

  • Clinical Research Site

    Sherman Oaks, California

  • Clinical Research Site

    Torrance, California

  • Clinical Research Site

    Walnut Creek, California

  • Clinical Research Site

    Colorado Springs, Colorado

  • Clinical Research Site

    Clermont, Florida

  • Clinical Research Site

    Doral, Florida

  • Clinical Research Site

    Gainesville, Florida

  • Clinical Research Site

    Jacksonville, Florida

  • Clinical Research Site

    Lauderhill, Florida

  • Clinical Research Site

    Miami Lakes, Florida

  • Clinical Research Site

    Orlando, Florida

  • Clinical Research Site

    Marietta, Georgia

  • Clinical Research Site

    Overland Park, Kansas

  • Clinical Research Site

    Boston, Massachusetts

  • Clinical Research Site

    Saint Charles, Missouri

  • Clinical Research Site

    Lincoln, Nebraska

  • Clinical Research Site

    Las Vegas, Nevada

  • Clinical Research Site

    Las Vegas, Nevada

  • Clinical Research Site

    Berlin, New Jersey

  • Clinical Research Site

    Cherry Hill, New Jersey

  • Clinical Research Site

    Princeton, New Jersey

  • Clinical Research Site

    Mount Kisco, New York

  • Clinical Research Site

    New York, New York

  • Clinical Research Site

    Raleigh, North Carolina

  • Clinical Research Site

    Cincinnati, Ohio

  • Clinical Research Site

    Kettering, Ohio

  • Clinical Research Site

    Oklahoma City, Oklahoma

  • Clinical Research Site

    Media, Pennsylvania

  • Clinical Research Site

    North Charleston, South Carolina

  • Clinical Research Site

    Memphis, Tennessee

  • Clinical Research Site

    Austin, Texas

  • Clinical Research Site

    Bellaire, Texas

  • Clinical Research Site

    Dallas, Texas

  • Clinical Research Site

    Dallas, Texas

  • Clinical Research Site

    San Antonio, Texas

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.